SARS-CoV 2: Clinical Trials

6 trials for SARS-CoV 2, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 unknown. 6 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 26Unknown 6
Phase 11Unknown 1
Phase 31Unknown 1

Follow SARS-CoV 2: new trials by email Literature Review of SARS-CoV 2 trials Research Report on SARS-CoV 2

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory in Treating COVID-19 Disease
Lactoferrin (Apolactoferrin), Placebo of excipient(s) will be administered - Corona Virus Infection, Middle East Respiratory Syndrome (MERS)
Phase 2UnknownNational Research Centre, Egypt5162022-02-012021-11-15
P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19
P2Et (Caesalpinia spinosa extract), Placebo - COVID, Coronavirus Infection
Phase 2 / Phase 3UnknownHospital Universitario San Ignacio1002020-09-302021-08-10
Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19
Masitinib, Isoquercetin, Best Supportive Care - SARS-CoV 2, COVID-19
Phase 2UnknownAB Science2002020-06-012023-02-06
Baricitinib Compared to Standard Therapy in Patients With COVID-19
Baricitinib Oral Tablet - Covid-19, SARS-CoV 2
Phase 2UnknownAzienda Ospedaliero, Universitaria Pisana1262020-05-202020-05-20
CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19
convalescent plasma - COVID-19, SARS-CoV 2
Phase 1 / Phase 2UnknownInstituto de Seguridad y Servicios Sociales de los Trabajadores del Estado902020-05-202020-06-05
Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora
Oxygen-ozone therapy, probiotic supplementation and Standard of care, SivoMixx (200 billion), Azithromycin - COVID, SARS-CoV 2
Phase 2UnknownRoberto Poscia MD, PhD1522020-03-262020-04-28

Narrower conditions

COVID-19 (5)  ·  Coronavirus Infections (3)  ·  Convalescence (1)  ·  Cytokine Release Syndrome (1)  ·  Pneumonia (1)  ·  Pneumonia, Viral (1)  ·  Respiratory Distress Syndrome (1)

Broader conditions

Coronaviridae Infections (6)  ·  Infections (6)  ·  Lung Diseases (6)  ·  Nidovirales Infections (6)  ·  RNA Virus Infections (6)  ·  Respiratory Tract Diseases (6)  ·  Respiratory Tract Infections (6)  ·  Virus Diseases (6)  ·  Pneumonia (5)  ·  Pneumonia, Viral (5)  ·  Coronavirus Infections (3)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Disease Attributes (1)  ·  Inflammation (1)

Interventions

Azithromycin (1)  ·  Hydroxychloroquine (1)  ·  Lactoferrin (1)  ·  Standard of Care (1)  ·  apolactoferrin (1)  ·  baricitinib (1)  ·  isoquercitrin (1)  ·  masitinib (1)

Sponsors

AB Science (1)  ·  Azienda Ospedaliero, Universitaria Pisana (1)  ·  Hospital Universitario San Ignacio (1)  ·  Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (1)  ·  National Research Centre, Egypt (1)  ·  Roberto Poscia MD, PhD (1)

Countries

Italy (2)  ·  Colombia (1)  ·  Egypt (1)  ·  France (1)  ·  Mexico (1)

Top investigators

Francesco Menichetti, MD (1)  ·  Francesco Pugliese, MD, PhD (1)  ·  Luis M Villela, MD (1)  ·  Pascal Chanez, MD (1)  ·  Rehab Hegazy, PhD (1)

Results publications

PMID 11023960, PMID 20370679, PMID 25457751, PMID 32032529, PMID 32125452, PMID 32150360, PMID 32219428, PMID 32228825, PMID 32251638, PMID 32303365, PMID 36048877, PMID 36160152, PMID 37117213, PMID 3898484